New hope for rare, aggressive cancers as national trial tests promising drug duo
NCT ID NCT06161532
Summary
This study is testing whether two existing cancer drugs, sacituzumab govitecan and atezolizumab, can help control rare and aggressive cancers of the bladder, urinary tract, kidney, and penis. The trial will enroll 60 adults to receive one or both drugs, given through an IV, to see if they can shrink tumors or slow their growth. The goal is to find a better treatment option for cancers that currently have few standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF THE BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.